Joerger M, Diem S, Wyss N, Koster KL, et al. Open-label nonrandomized phase IB study to characterize the safety and recommended dose of tinostamustine in combination with nivolumab in patients with advanced melanoma (ENIgMA). Melanoma Res 2025 Apr 17. doi: 10.1097/CMR.0000000000001040.
PMID: 40265641